StockDuty ← Dashboard Nov 12, 2026 12:52 AM ET
SignalEarnings

$MDGL (MADRIGAL PHARMACEUTICALS) — 8-K: MDGL Q3 FY26: EPS $1.83 vs $-1.09 consensus — a +268.3% blowout beat as Rezdiffra tops $1B YTD

MDGL
$427.39
+0.51%
Madrigal posted Q3 FY26 GAAP EPS of $1.83, crushing the $-1.09 consensus by $2.92 (+268.3%) and marking its first profitable quarter. Revenue came in at $431M, up 50.1% YoY, driven by increased demand for Rezdiffra in the U.S., with net income of $55M.
Madrigal posted Q3 FY26 GAAP EPS of $1.83, crushing the $-1.09 consensus by $2.92 (+268.3%) and marking its first profitable quarter. Revenue came in at $431M, up 50.1% YoY, driven by increased demand
Sources